Extravasation of vancomycin away from the peripheral vein of administration

The observation of AT III deficiency in premature neonates with Idiopathic Respiratory Distress Syndrome (IRDS), suggests a positive predictive value for a poor outcome. The underlying diffuse intravascular coagulation could generate serious hemorrhagic complications like Peri/Intraventricular Hemorrhage (IVH).A prospective study was performed in consecutively born neonates to assess the predictive value of low AT III for theoccurrence of IVH, (gr. III/IV), IRDS, and death. Eighty-one neonates were included in the study during a period of 5 months. AT III levels were determined immediately after birth by a chromogenic substrate assay. Values in umbilical cord blood were identical with values in capillary or peripheral vein blood samples taken within 6 hours after birth. There was no correlation between AT III values and gestational age (r: 0.18). Twenty-four neonates with IRDS showed a mean AT III value of 0.23 U/ml (S. D. ± 0.07 U/ml) which was significantly lower than a mean AT III value of 0.35 U/ml (S. D. ± 0.1 U/ml) for neonates without IRDS (p ≺0.00005). When IVH gr. III/IV was diagnosed in neonates having IRDS (8/24) no significant difference in mean AT IIIact was observed with respect to jnean AT III levels of remaining neonates without this complication. No death occurred in neonates without IRDS. Mean AT IIIact (0.21 U/ml) in neonates with IRDS who died (9/24) was low compared with mean AT III levels of neonates with IRDS who survived (0.25 U/ml), but did not reach significance (p≻0.1). Assuming a critical value of AT III of 20% a positive predictive value of 89% for IRDS, 44% for IVH, and 56% for death was calculated. It is concluded that low AT Illact levels have a high predictive value for IRDS.

Download Full-text

Clinical observations of bone marrow transfusion for promoting bone marrow reconstruction after chemotherapy for AIDS-related lymphoma

BMC Immunology ◽

10.1186/s12865-021-00399-8 ◽

2021 ◽

Vol 22 (1) ◽

Author(s):

Yixuan Liu ◽

Suhong Xie ◽

Lei Li ◽

Yanhui Si ◽

Weiwei Zhang ◽

...

Keyword(s):

Bone Marrow ◽

Immune System ◽

T Lymphocytes ◽

Peripheral Blood ◽

Autologous Bone Marrow ◽

Control Group ◽

Peripheral Vein ◽

Significant Difference ◽

Autologous Bone ◽

Aids Related Lymphoma

Abstract Background This study investigates the effect of autologous bone marrow transfusion (BMT) on the reconstruction of both bone marrow and the immune system in patients with AIDS-related lymphoma (ARL). Methods A total of 32 patients with ARL participated in this study. Among them, 16 participants were treated with conventional surgery and chemotherapy (control group) and the remaining 16 patients were treated with chemotherapy followed by autologous bone marrow transfusion via a mesenteric vein (8 patients, ABM-MVI group) or a peripheral vein (8 patients, ABM-PI group). Subsequently, peripheral blood and lymphocyte data subsets were detected and documented in all patients. Results Before chemotherapy, no significant difference in indicators was observed between three groups of ARL patients. Unexpectedly, 2 weeks after the end of 6 courses of chemotherapy, the ABM-MVI group, and the ABM-PI group yielded an increased level of CD8+T lymphocytes, white blood cells (WBC), and platelet (PLT) in peripheral blood in comparison to the control group. Notably, the number of CD4+T lymphocytes in the ABM-PI group was significantly higher than that in the other two groups. Additionally, no significant difference in haemoglobin levels was observed before and after chemotherapy in both the ABM-MVI and ABM-PI groups, while haemoglobin levels in the control group decreased significantly following chemotherapy. Conclusions Autologous bone marrow transfusion after chemotherapy can promote the reconstruction of both bone marrow and the immune system. There was no significant difference in bone marrow recovery and reconstruction between the mesenteric vein transfusion group and the peripheral vein transfusion group.

Download Full-text

Venous procedures and acute peripheral vein thrombosis: The past and future of the interventional radiologist

Diagnostic and Interventional Imaging ◽

10.1016/j.diii.2012.10.002 ◽

2012 ◽

Vol 93 (10) ◽

pp. 723-724

Author(s):

J.-P. Beregi

Keyword(s):

Peripheral Vein ◽

Interventional Radiologist ◽

Vein Thrombosis ◽

The Past

Download Full-text

Portal and Peripheral Vein Immunoreactive Glucagon Concentrations After Arginine or Glucose Infusions

Diabetes ◽

10.2337/diab.23.3.199 ◽

1974 ◽

Vol 23 (3) ◽

pp. 199-202 ◽

Cited By ~ 84

Author(s):

W. G. Blackard ◽

N. C. Nelson ◽

S. S. Andrews

Keyword(s):

Peripheral Vein

Download Full-text

Topical nonsteroidal anti-inflammatory gel for the prevention of peripheral vein thrombophlebitis.

Anaesthesia ◽

10.1111/j.1365-2044.1992.tb02174.x ◽

1992 ◽

Vol 47 (4) ◽

pp. 324-326 ◽

Cited By ~ 19

Author(s):

J. J. PAYNE-JAMES ◽

M. J. BRAY ◽

S. KAPADIA ◽

S. K. RANA ◽

D. MCSWIGGAN ◽

...

Keyword(s):

Peripheral Vein ◽

Anti Inflammatory

Download Full-text

Cancer and Peripheral Deep Vein Thrombosis are Both Independent Diseases Causes, Pathogenesis, Conclusions

10.47363/jcrr/2020(2)103 ◽

2020 ◽

Vol 2 (1) ◽

pp. 1-3

Author(s):

Drozdova Elena Viktorovna ◽

Keyword(s):

Deep Vein Thrombosis ◽

World Health Organization ◽

Cause Of Death ◽

Controlled Trial ◽

World Health ◽

Peripheral Vein ◽

Vein Thrombosis ◽

Sickness Rate ◽

Health Organization ◽

Deep Vein

There is an undisputed thesis: CANCER has an often COMPLICATION such as DEEP VEIN THROMBOSIS. Cancer is the second leading cause of death globally, and is responsible for an estimated 9.6 million deaths in 2018. (according to World Health Organization). Sickness rate of deep vein thrombosis is approximately 100 per 100 000 population annually. Sickness rate of cancer in different countries is approximately 130-500 per 100 000 population annually. Thus, if deep vein thrombosis is considered to be a complication of cancer we must identify both these diseases simultaneously with frequency of 20 -76.9% The Research Objective To determine whether peripheral vein thromboses are the complications of cancer. The Method of the Research Randomized prospective parallel controlled trial.

Download Full-text

SERUM SOMATOMEDIN ACTIVITY MEASURED AS SULPHATION FACTOR IN PERIPHERAL, HEPATIC AND RENAL VEINS OF PATIENTS WITH ALCOHOLIC CIRRHOSIS

Acta Endocrinologica ◽

10.1530/acta.0.0880729 ◽

1978 ◽

Vol 88 (4) ◽

pp. 729-736 ◽

Cited By ~ 11

Author(s):

R. M. Schimpff ◽

D. Lebrec ◽

M. Donnadieu ◽

A. M. Repellin

Keyword(s):

Growth Hormone ◽

Chick Embryo ◽

Hepatic Vein ◽

Peripheral Blood ◽

Renal Vein ◽

Alcoholic Hepatitis ◽

Alcoholic Cirrhosis ◽

Peripheral Vein ◽

Renal Veins ◽

Serum Samples

ABSTRACT Serum somatomedin (SM) activity, measured as sulphation factor on chick embryo cartilage, and growth hormone (GH) levels were measured in peripheral, hepatic and renal veins of 23 patients with alcoholic cirrhosis. SM activity (mean ± sem) was 0.65 ± 0.05 U/ml in peripheral vein, 0.59 ± 0.04 U/ml in hepatic vein, and 0.74 ± 0.07 U/ml in renal vein. Mean GH levels were respectively 2.8, 2.5 and 3.1 ng/ml. Compared to peripheral vein, SM increase in renal vein was 19% (P < 0.05). Serum SM activity was significantly lower in 13 patients with alcoholic hepatitis associated with cirrhosis than in other 10 patients (P < 0.02 in hepatic blood and P < 0.05 in peripheral blood). The decrease of SM activity seems related to cytolysis and hepato-cellular insufficiency. At last, in patients with alcoholic hepatitis, SM activity was lower in the hepatic vein than in the peripheral vein (P < 0.05). The cause of this difference remains under discussion, no SM inhibitors being found in the serum samples used in this study.

Download Full-text

Comparison of intraperitoneal, intraportal and intravenous insulin infusion

Acta Endocrinologica ◽

10.1530/acta.0.0950500 ◽

1980 ◽

Vol 95 (4) ◽

pp. 500-504 ◽

Cited By ~ 6

Author(s):

J. S. Dirch Poulsen ◽

Mogens Smith ◽

Marja Deckert ◽

Torsten Deckert

Keyword(s):

Portal Vein ◽

Peritoneal Cavity ◽

Plasma Insulin ◽

Insulin Infusion ◽

Peripheral Vein ◽

Intravenous Insulin ◽

Intraperitoneal Insulin ◽

Arterial Plasma ◽

Mini Pump

Abstract. In order to avoid complications induced by long-term infusions of insulin into the portal vein, we examined the effect of intraperitoneal (ip) insulin infusion on arterial plasma insulin and glucose concentrations in 6 pigs, made diabetic by a constant intravenous (iv) infusion of glucose, epinephrine and propranolol. Insulin was infused by an electromechanical programmable mini-pump (Pharmaject Micro Infusion System®, Pharmacia Electronics) as a booster injection of 46 mU highly purified porcine insulin Leo®/kg body weight, followed by 3 infusion periods of 30 min each with stepwise decreasing infusion rates of 1.6–0.8 and 0.2 mU/kg/min in a total volume of 192 μ1. Insulin was infused in a peripheral vein, a portal vein and into the peritoneal cavity. A steep rise of arterial plasma insulin was demonstrated followed by a slow and identical decline in the peripheral and portal experiments, whereas only a small increase of plasma insulin was seen in the ip experiment, indicating insufficient absorption of insulin from the peritoneal cavity. The decrease of plasma glucose was identical in the peripheral and portal vein experiments, indicating that insulin infused in the portal vein does not seem to have a higher hypoglycaemic effect, than insulin infused in a peripheral vein. Intraperitoneal insulin infusion seems not to be a practical substitute for iv insulin infusion.

Download Full-text